Literature DB >> 15988645

Prostate cancer and sexually transmitted diseases: a meta-analysis.

Marcia L Taylor1, Arch G Mainous, Brian J Wells.   

Abstract

BACKGROUND: Prostate cancer is the most common neoplasm of American men and the second most common cause of cancer-related deaths. Research suggests that infection and subsequent inflammation may be an important risk factor in the pathogenesis of prostate cancer. In this meta-analysis, we examine the current epidemiological evidence for the association between specific sexually transmitted diseases (STDs) and prostate cancer.
METHODS: Using an English language search of Medline and CINAHL (Cumulative Index to Nursing and Allied Health) since 1966, 29 case-control studies were identified. These studies included a total of 6,022 cases of prostate cancer and 7,320 controls. Using Review Manager, combined odds ratios (ORs) were calculated for any STDs, gonorrhea, syphilis, and human papillomavirus (HPV) for prostate cancer.
RESULTS: Significant elevated ORs for prostate cancer were demonstrated for any STDs (1.48, 95% confidence interval [CI] 1.26-1.73), gonorrhea (1.35, 95% CI 1.05-1.83), and human papillomavirus (1.39, 95% CI 1.12-2.06).
CONCLUSIONS: This meta-analysis provides evidence of a higher rate of prostate cancer in men with a history of an exposure to gonorrhea, HPV, or any STD. Further research, especially with cohort studies, is required to confirm this potentially modifiable risk factor.

Entities:  

Mesh:

Year:  2005        PMID: 15988645

Source DB:  PubMed          Journal:  Fam Med        ISSN: 0742-3225            Impact factor:   1.756


  59 in total

1.  Circumcision reduces prostate cancer risk.

Authors:  Brian J Morris; Jake H Waskett
Journal:  Asian J Androl       Date:  2012-05-28       Impact factor: 3.285

2.  Association of male circumcision with risk of prostate cancer: a meta-analysis.

Authors:  N Pabalan; E Singian; H Jarjanazi; A Paganini-Hill
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-07-28       Impact factor: 5.554

Review 3.  Treatment for PSA screen-detected prostate cancer: what are the options?

Authors:  R Tim D Oliver; David E Neal
Journal:  Nat Clin Pract Urol       Date:  2009-01-27

Review 4.  The inflammatory microenvironment and microbiome in prostate cancer development.

Authors:  Karen S Sfanos; Srinivasan Yegnasubramanian; William G Nelson; Angelo M De Marzo
Journal:  Nat Rev Urol       Date:  2017-10-31       Impact factor: 14.432

5.  [Risks and prevention of prostate cancer. Commentary on the new S3 guideline].

Authors:  B J Schmitz-Dräger; E Bismarck; G Lümmen
Journal:  Urologe A       Date:  2010-02       Impact factor: 0.639

6.  Human papillomavirus infection and bladder cancer risk: a meta-analysis.

Authors:  Ni Li; Lin Yang; Yawei Zhang; Ping Zhao; Tongzhang Zheng; Min Dai
Journal:  J Infect Dis       Date:  2011-07-15       Impact factor: 5.226

7.  Trichomonas vaginalis homolog of macrophage migration inhibitory factor induces prostate cell growth, invasiveness, and inflammatory responses.

Authors:  Olivia Twu; Daniele Dessí; Anh Vu; Frances Mercer; Grant C Stevens; Natalia de Miguel; Paola Rappelli; Anna Rita Cocco; Robert T Clubb; Pier Luigi Fiori; Patricia J Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-19       Impact factor: 11.205

Review 8.  Omega-3 fatty acids, genetic variants in COX-2 and prostate cancer.

Authors:  Adam C Reese; Vincent Fradet; John S Witte
Journal:  J Nutrigenet Nutrigenomics       Date:  2009-09-23

Review 9.  MSMB variation and prostate cancer risk: clues towards a possible fungal etiology.

Authors:  Siobhan Sutcliffe; Angelo M De Marzo; Karen S Sfanos; Martin Laurence
Journal:  Prostate       Date:  2014-01-24       Impact factor: 4.104

10.  Prostatitis, sexually transmitted diseases, and prostate cancer: the California Men's Health Study.

Authors:  Iona Cheng; John S Witte; Steven J Jacobsen; Reina Haque; Virginia P Quinn; Charles P Quesenberry; Bette J Caan; Stephen K Van Den Eeden
Journal:  PLoS One       Date:  2010-01-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.